nby: the income statement

MyFinsight

NovaBay Pharmaceuticals, Inc. (NBY)

For the quarter ending 2025-06-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

	2025-06-30	2024-09-30	2024-06-30
Total sales, net	-	2,441	2,400
Cost of goods sold	-	848	808
Us-gaap_grossprofit	-	1,593	1,592
Sales and marketing	-	947	1,019
Research and development	-	4	9
Impairment of long-lived assets	-	-	-
General and administrative	1,891	1,703	1,617
Total operating expenses	1,891	2,654	2,645
Operating loss	-1,891	-1,061	-1,053
Non-cash (loss) gain on changes in fair value of warrant liabilities	-	-	80
Accretion of interest and amortization of discounts on convertible notes	-	138	300
Non-cash loss on change in fair value of embedded derivative liability	-	-	83
Other expense, net	-73	-	-69
Extinguishment of secured convertible notes	-	-13	-
Net loss from continuing operations	-1,964	-1,212	-1,585
Net income from discontinued operations, net of taxes (notes 14, 15 and 16)	42	-	-
Net (loss) income	-1,922	-1,212	-1,585
Less increase to accumulated deficit due to adjustment to preferred stock conversion price	-	-	-
Us-gaap_warrantdownroundfeaturedecreaseinnetincomelosstocommonshareholderamount	-	1,005	-
Net (loss) income attributable to common stockholders	-1,922	-2,217	-1,585

Basic (and diluted for net loss) (in shares)	5,818,000	3,710,000	1,155,000
Diluted earnings (loss) per share attributable to common stockholders (in shares)	5,818,000	-	-
Us-gaap_earningspersharebasic	-0.33	-0.6	-1.37
Us-gaap_earningspersharediluted	-0.33	-	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)